By Garrett Mott (December 13, 2017, 4:59 PM EST) -- With increasing monetary penalties and tighter corporate integrity agreements becoming the norm in False Claims Act ("FCA") cases, how can healthcare organizations best learn from recent cases? To answer that question, this article examines three recent FCA settlements — Mylan Inc.'s half-billion dollar settlement regarding EpiPen price increases; Pacific Alliance Medical Center's settlement regarding an alleged physician kickback scheme; and Galena Biopharma's settlement regarding the hot-button opioid epidemic. The following lessons, although learned in the school of hard knocks by three different types of healthcare organizations, offer us a far cheaper education. Each teaches us something different, but all are of equal importance:...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
